Drug Database
CO

collagen (Gelfix / Biopad / Condress)

✓ Approved

Merck & Co. · 治疗药物

什么是 collagen?

collagen 是一种治疗药物,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Gelfix, Biopad, Condress
公司Merck & Co.
给药途径Topical
状态Approved

治疗适应症

collagen 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
General disorders and administration site conditionsImpaired healing✓ Approved
Skin and subcutaneous tissue disordersDiabetic foot✓ Approved
Skin and subcutaneous tissue disordersDecubitus ulcer✓ Approved
Vascular disordersPeripheral venous disease✓ Approved

相关研究文献

PubMedBiopolymers2026-10-26

Designed Protein-Based Physical Crosslinker for Triple Helical Collagen Biomaterials.

de Souza Amanda A, Amaral Gustavo Oliva GO, Zheng Chuanbao C, de Haas Robbert Jan RJ et al.

Collagen plays a pivotal role in animal body structure, but hydrogels of reconstituted collagens often have poor mechanical performance. Chemical crosslinking or the addition of other biopolymers are often used as a remedy. Inspired by the many natural collagen-interacting proteins that modify the mechanics of collagen hydrogels, we explore protein-based physical crosslinking of collagen as a route to modulate the mechanics of collagen hydrogels. A protein-based crosslinker for collagen was designed based on an adhesion domain from Staphylococcus aureus. A tetramerization domain was coupled to an elastin-like polypeptide as a spacer, followed by the collagen adhesion domain, yielding a tetrafunctional crosslinking. Circular Dichroism spectroscopy shows that the crosslinker has the expected secondary structure. Using quartz crystal microbalance, we demonstrate the tetrameric crosslinker binds rat tail Collagen I and fish collagen, even though the latter is largely denatured as evidenced by circular dichroism spectroscopy. Rheometry shows strong enhancement of elastic moduli and strain-stiffening for rat tail collagen hydrogels, but smaller effects on the reduced fish collagen. Because CNA35 recognizes the collagen triple helix, this contrast indicates that the crosslinker acts specifically on triple-helical collagen, and points to the importance of improved extraction protocols for alternative collagens that preserve native triple-helical conformations.

PMID 42928497
阅读全文 →
PubMedFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026-10-26

Autophagy-Controlled Collagen I Metabolism and ECM Homeostasis: From Molecular Mechanisms to Fibrotic Dysregulation and Therapy.

Liu Yuanyuan Y, Wang Lingwei L, Chen Shuyu S, Chen Shanze S et al.

Fibrotic diseases are characterized by persistent extracellular matrix (ECM) remodeling and excessive accumulation of fibrillar collagens, particularly Type I collagen (Col I), which collectively drive tissue stiffening, architectural distortion, and progressive organ dysfunction. However, pathological Col I dysregulation is not limited to overproduction or deposition; it may also involve defective folding, impaired trafficking, abnormal secretion, insufficient degradation, or altered collagen availability in specific disease contexts. Emerging evidence identifies autophagy as a central regulator of this network. Beyond its canonical degradative function, autophagy integrates procollagen quality control, endoplasmic reticulum (ER) stress adaptation, selective ER-phagy, and lysosome-dependent collagen turnover. Among these processes, selective ER-phagy eliminates misfolded or surplus procollagen, whereas secretory autophagy and lysosomal turnover determine whether collagen is exported, retained, or degraded. In fibrotic disease, impaired ER-phagy, maladaptive secretory autophagy, and defective lysosomal flux collectively promote ER stress, aberrant collagen secretion, ECM accumulation, and matrix stiffening. This review summarizes current understanding of the autophagy-Col I axis across the collagen lifecycle, discusses how its dysregulation contributes to fibrotic remodeling, and highlights checkpoint-focused therapeutic strategies aimed at restoring collagen clearance and ECM homeostasis.

PMID 42928995
阅读全文 →
PubMedGels (Basel, Switzerland)2026-10-26

In Vitro Modeling of Tendon with Type I Collagen Scaffolds.

Arnold Katherine M KM, Schmidt Tannin T, Deymier Alix A

In vitro collagen scaffolds provide simplified systems for investigating tendon properties without the use of animal models. However, common scaffold processing approaches, including dehydration and chemical crosslinking, can alter scaffold water content, molecular structure, thermal, and mechanical properties in ways that are not fully understood. In this study, we investigate the influence of ethanol-induced dehydration and genipin crosslinking on type I collagen scaffolds and compare their chemical and thermal properties with native murine Achilles tendons. Fourier Transform Infrared Spectroscopy (FTIR) demonstrated that ethanol treatment reduced molecularly bound water (from 127.3 to 48.0 a.u.) and caused shifts in amide bands (Amide I upshift, Amide II & III downshifts) commonly associated with dehydration, bringing values closer to those of native tendon. Genipin crosslinking further increased similarity to tendon, particularly in thermal behavior as measured by thermogravimetric analysis (TGA). Ten millimolar genipin-treated scaffolds pre-rehydration most closely approximated tendon but diverged post-rehydration. Crosslinking strongly restricted scaffold rehydration (final swelling factor 44.46 vs. 4.06) and altered mechanical properties. Together, these results demonstrate that dehydration and crosslinking influence collagen scaffolds across molecular, thermal, hydration, and mechanical properties. Careful control of these processing conditions, particularly hydration history, is therefore important for collagen-based in vitro models mimicking physicochemical features of native tendon.

PMID 42929906
阅读全文 →
PubMedGels (Basel, Switzerland)2026-10-26

A Five-Decade Perspective on the Evolution of Gelatin and Collagen Technologies and Materials Used in Medical Devices.

Woodroof Aubrey A, Naughton Gail G, Montgomery Michelle M

Collagen and gelatin have been incorporated into medical devices for more than five decades because they combine biological familiarity with practical material versatility. This narrative historical perspective examines how these materials progressed from hemostatic agents, wound coverings, and collagen-stabilized devices toward more deliberately engineered wound-contacting matrices and regenerative biomaterials. The discussion integrates selected peer-reviewed literature with first-hand historical knowledge from authors involved in the development of several technologies. The first part summarizes the material basis for collagen and gelatin use, including their structural differences, biocompatibility, biodegradability, cell interactions, absorbency, processability, and emerging recombinant or animal-free platforms. The second part summarizes selected clinical developments, beginning with collagen fixation chemistry for tissue heart valves and then examining Biobrane, TransCyte, AWBAT, and PermeaDerm as examples of evolving temporary skin-substitute design. Across these technologies, device performance depended not only on the biological material but also on adherence, fluid transport, porosity, transparency, manufacturability, and clinical handling. The available evidence is heterogeneous and includes preclinical studies, clinical comparisons, and first-hand development reports. Future progress will require better material characterization, independent and adequately powered clinical studies, and designs that balance biological function with manufacturability, cost, regulatory clarity, and ease of use.

PMID 42929930
阅读全文 →
PubMedTurkish journal of ophthalmology2026-10-26

Anatomopathological Aspects and Clinical Correlation of Conjunctival Bleb Fibrosis Following Encapsulation of a Biodegradable Collagen Matrix Implant in Glaucoma Surgery.

Castro-Roger Luisa L, Labay-Tejado Sara S, Suárez Xavier X, Lop Gros Joan J et al.

This study reports a case series of glaucoma patients in whom a biodegradable collagen-glycosaminoglycan implant (Ologen®) failed to prevent fibrosis after non-penetrating deep sclerectomy (NPDS) and describes the associated histopathological findings. This single-centre retrospective study included four patients with progressive glaucoma and inadequate intraocular pressure (IOP) control despite maximal medical therapy. All underwent NPDS with implantation of a collagen-glycosaminoglycan matrix and adjunctive mitomycin C. Postoperative follow-up included IOP monitoring, slit-lamp examination, and photographic documentation. Patients with bleb failure required surgical revision, and excised tissue, including the implant and surrounding Tenon's capsule, was analysed histologically. All cases developed progressive bleb fibrosis. The implants remained intact, encapsulated by dense fibrotic tissue ("ring-of-steel" appearance), with minimal fibroblast infiltration, extensive collagen deposition, and no significant degradation for up to three years. These findings highlight variability in tissue response and suggest a potential role of patient-specific fibrotic predisposition in surgical outcomes.

PMID 42929100
阅读全文 →
PubMedDentistry journal2026-10-26

Xenogeneic Grafts Combined with Platelet Concentrates: Effects on Bone Microarchitecture and Collagen Maturation.

Braga Wanderson Thalles de Souza WTS, Martins Ulli da Costa Cunha UDCC, Sávio Débora de Souza Ferreira DSF, Silva Lucia Moitrel Pequeno da LMPD et al.

Background: This study assessed the impact of xenogeneic bone grafts (XEN), either utilized alone or combined with autologous platelet concentrates (APCs) prepared using three different centrifugation protocols, on the healing of critical-size defects (CSDs) in rat calvaria. Methods: Forty rats were assigned to five groups (n = 8): Control, XEN, XEN + L-PRF, XEN + A-PRF, and XEN + Bio-PRF. Blood concentrates were prepared by centrifuging blood collected via cardiac puncture: L-PRF (~700 g for 12 min), A-PRF (~208 g for 14 min), and Bio-PRF (~700 g for 8 min). Defects (5 mm diameter) in the right parietal bone of each rat were filled with blood clot, XEN, or XEN combined with L-PRF, A-PRF, or Bio-PRF. Animals were euthanized 60 days post-surgery, and the calvariae were analyzed using histomorphometry and micro-CT. The percentage of mature and immature collagen fibers was analyzed using Picrosirius red staining under polarized light microscopy. Results: Groups XEN-A-PRF, XEN-L-PRF, and XEN-Bio-PRF presented higher bone volume (BV/TV) than the control group (14.35 ± 6.42%, 11.96 ± 4.68%, and 14.92 ± 3.47%, respectively, vs. 4.13 ± 2.25%; p < 0.05). These groups also presented lower bone porosity (BP) than the control group (p < 0.05). The XEN group did not show different values of BV/TV and BP compared to the control group. Only the XEN + A-PRF and XEN + Bio-PRF groups showed a higher percentage of mature collagen fibers (red color) compared to the XEN and control groups (p < 0.05). The control and XEN groups showed a higher amount of immature collagen fibers (green color) compared to the XEN + A-PRF, XEN + L-PRF, and XEN + Bio-PRF groups (p < 0.05). Conclusions: It can be concluded that CSDs treated with XEN combined with APCs presented a more favorable bone microarchitecture than untreated CSDs after a 60-day healing period. Furthermore, CSDs treated with XEN combined with A-PRF or Bio-PRF showed greater collagen maturation than those treated with XEN alone, suggesting that the centrifugation protocol used for preparing APCs may be a decisive factor for the quality of the collagen matrix in newly formed bone tissue.

PMID 42930441
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多collagen